A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

Purpose: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy, would enhance efficacy versus placebo in TP53-mutated ovarian cancer. Patients and Methods: Following safety run-in, this do...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2020-09, Vol.26 (18), p.4767-4776
Hauptverfasser:	Oza, Amit M., Estevez-Diz, Maria, Grischke, Eva-Maria, Hall, Marcia, Marme, Frederik, Provencher, Diane, Uyar, Denise, Weberpals, Johanne I., Wenham, Robert M., Laing, Naomi, Tracy, Michael, Freshwater, Tomoko, Lee, Mark A., Liu, Ji, Qiu, Jingjun, Rose, Shelonitda, Rubin, Eric H., Moore, Kathleen
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences & Biomedicine Oncology Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!